Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$174.27 USD

174.27
898,400

+1.27 (0.73%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $174.26 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (66 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Bruker (BRKR) Partners With NovAliX to Boost Drug Discovery

by Zacks Equity Research

Bruker (BRKR) invests in NovAliX to accelerate advancements in drug discovery, combining cutting-edge biophysical methods and technologies to develop new treatments and enhance biopharma solutions.

Zacks Equity Research

Prestige Consumer's (PBH) Q1 Earnings Beat, Margins Shrink

by Zacks Equity Research

Prestige Consumer (PBH) first-quarter sales bear the brunt of the ongoing supply chain challenges in the Clear Eyes business.

Zacks Equity Research

Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised

by Zacks Equity Research

Insulet's (PODD) second-quarter performance benefits from the continued high demand for Omnipod 5.

Zacks Equity Research

OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down

by Zacks Equity Research

Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.

Zacks Equity Research

Stryker's (SYK) Pangea System to Enhance Plating Solutions

by Zacks Equity Research

Stryker (SYK) announces the launch of its Pangea Plating System, which is likely to provide solutions for internal fixation and stabilization of bone fractures.

Zacks Equity Research

Envista (NVST) Q2 Earnings & Revenues Miss, Margins Fall

by Zacks Equity Research

Envista's (NVST) Spark division sales witness a slowdown in the second quarter due to the deferment of a larger portion of case revenues.

Zacks Equity Research

Vicarious Surgical (RBOT) Partners LSU Health New Orleans

by Zacks Equity Research

Vicarious Surgical (RBOT) teams up with LSU Health New Orleans to advance its V1.0 surgical robot. It aims to file for FDA approval by 2026.

Zacks Equity Research

Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up

by Zacks Equity Research

Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.

Zacks Equity Research

National Vision (EYE) Tops Q2 Earnings, Lowers '24 Outlook

by Zacks Equity Research

National Vision (EYE) delivers an earnings beat in the second quarter of 2024 and announces new transformative actions for long-term growth.

Zacks Equity Research

Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised

by Zacks Equity Research

Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term revenue growth rate target.

Zacks Equity Research

Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down

by Zacks Equity Research

Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.

Zacks Equity Research

Smith & Nephew (SNN), HOPCo to Enhance Musculoskeletal Care

by Zacks Equity Research

Smith & Nephew (SNN) announces a collaboration with HOPCo to focus on enhancing solutions for ASC customers, physicians, and patients through the latter's digital health and analytics platforms.

Zacks Equity Research

DaVita (DVA) Q2 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

DaVita's (DVA) robust segmental revenues drive its second-quarter performance.

Zacks Equity Research

Masimo (MASI) Q2 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Strength in Healthcare revenues drive Masimo's (MASI) second-quarter results.

Zacks Equity Research

Zimmer Biomet (ZBH) Beats on Q2 Earnings, Cuts Revenue View

by Zacks Equity Research

Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.

Zacks Equity Research

Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Inogen's (INGN) second-quarter 2024 results reflect significant improvement in the top and bottom lines, driven by strong international and domestic business-to-business sales.

Zacks Equity Research

Inspire Medical (INSP) Q2 Earnings Beat, Gross Margin Rises

by Zacks Equity Research

Inspire Medical (INSP) reports strong second-quarter results, reflecting a 30% revenue increase. Its new technology and expanded U.S. presence promise growth and enhanced patient care.

Zacks Equity Research

STERIS (STE) Q1 Earnings Beat Estimates, Operating Margin Falls

by Zacks Equity Research

STERIS' (STE) first-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of the operating margin is concerning.

Zacks Equity Research

Globus Medical (GMED) Q2 Earnings Top Estimates, '24 View Up

by Zacks Equity Research

Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.

Zacks Equity Research

CVS Health (CVS) Beats Q2 Earnings, Narrows '24 EPS Outlook

by Zacks Equity Research

CVS Health (CVS) delivers a year-over-year improvement in revenues, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments.

Zacks Equity Research

Bruker (BRKR) Q2 Earnings Meet Mark, '24 Revenue Outlook Raised

by Zacks Equity Research

Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.

Zacks Equity Research

Stryker (SYK) Completes MOLLI's Acquisition to Boost Business

by Zacks Equity Research

Stryker (SYK) completes of the acquisition of MOLLI, a privately held company, to strengthen its commitment to advancing surgical solutions in breast cancer care.

Zacks Equity Research

CooperCompanies (COO) Acquires obp Surgical to Boost Portfolio

by Zacks Equity Research

CooperSurgical, a unit of CooperCompanies (COO), acquires obp Surgical for $100 million, adding innovative single-use surgical retractors and suction devices to its portfolio.

Zacks Equity Research

IDEXX (IDXX) Q2 Earnings Miss Estimates, 2024 View Down

by Zacks Equity Research

IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.

Zacks Equity Research

Henry Schein (HSIC) Q2 Earnings Surpass, 2024 Guidance Slashed

by Zacks Equity Research

Henry Schein's (HSIC) second-quarter results reflect an improvement in sales trends in distribution businesses.